Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P10721
UPID:
KIT_HUMAN
Alternative names:
Piebald trait protein; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Alternative UPACC:
P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99
Background:
The Mast/stem cell growth factor receptor Kit, known as c-Kit, plays a pivotal role in cell survival, proliferation, hematopoiesis, and melanogenesis. It acts as a receptor for KITLG/SCF, activating multiple signaling pathways, including AKT1, MAPK, and STAT family members, crucial for various cellular functions.
Therapeutic significance:
c-Kit's involvement in diseases like Piebald trait, Gastrointestinal stromal tumor, Testicular germ cell tumor, Acute myelogenous leukemia, and Mastocytosis underscores its therapeutic potential. Targeting c-Kit could lead to innovative treatments for these conditions.